First Blood-Based Lung Cancer EGFR Test Gets FDA Green Light
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.
You may also be interested in...
Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
Diagnostics In 2015: Past Trends Coalesce, New Roads Open
The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.
New Products In Brief
New cancer companion diagnostic approved. Biotronik’s Ilesto 7 ICD and CRT-D earns FDA approval. More new product announcements.